Japan is one of the regions that stands at a crucial juncture as numerous new disease- modifying therapies move through Phase 2 and 3 trials to treat IgAN. Using Ipsos’ IgAN Therapy Monitor data, this report explores current treatment approaches and patient journeys, providing insights into nephrologist practices and decision making against the backdrop of these imminent therapeutic advancements.
Through social listening analysis of three years of hereditary angioedema (HAE) patient and caregiver conversations, this report captures the authentic voice across the diagnostic journey, treatment landscape, and support ecosystem, revealing where the system is failing and where meaningful intervention can make a measurable difference in quality of life.
Treatment for ATTR-CM and ATTR-PN took a significant step forward with the approval of the first targeted therapies in 2018/2019. With label and access expansions underway, and new MoAs on the horizon, top-level physician-stated and patient-level insights from Ipsos’ ATTR Therapy Monitor provide visibility of the evolving landscapes of these two conditions.